Cheri Andrews
Family Medicine · Arlington, TXNPI 1437110418
Payments from drug & device makers
Across 238 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$856
- GSK$453
- Lilly USA, LLC$371
- Pfizer$320
- Novo Nordisk$264
- Boehringer Ingelheim$264
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $856 |
| GSK | 27 | $453 |
| Lilly USA, LLC | 22 | $371 |
| Pfizer | 17 | $320 |
| Novo Nordisk | 16 | $264 |
| Boehringer Ingelheim | 15 | $264 |
| Bayer | 9 | $149 |
| Amgen | 7 | $117 |
| Astellas Pharma US Inc | 6 | $90 |
| Johnson & Johnson | 5 | $88 |
| Abbott | 5 | $82 |
| AstraZeneca | 5 | $76 |
| Teva Pharmaceuticals USA, Inc. | 5 | $60 |
| Amarin Pharma, Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Merck | 3 | $35 |
| Novartis | 2 | $35 |
| Dexcom, Inc. | 2 | $30 |
| Antares Pharma, Inc. | 2 | $27 |
| Insulet Corporation | 2 | $25 |
| Genentech USA, Inc. | 2 | $24 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Mannkind Corporation | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Medtronic | 1 | $19 |
| IBSA Pharma Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Echosens North America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,714 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 185 | $216,551 |
| MounjaroTirzepatide | 132 | $163,288 |
| JardianceEmpagliflozin | 99 | $104,200 |
| JanuviaSitagliptin Phosphate | 109 | $95,000 |
| EliquisApixaban | 68 | $52,603 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $30,109 |
| LinzessLinaclotide | 33 | $27,460 |
| MyrbetriqMirabegron | 38 | $26,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,445 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $21,456 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $16,235 |
| RybelsusSemaglutide | 13 | $14,610 |
| XareltoRivaroxaban | 19 | $14,002 |
| Repatha SureclickEvolocumab | 15 | $13,877 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $264 | $231,161198 claims |
| Lilly USA, LLCMounjaro | $371 | $163,288132 claims |
| Boehringer IngelheimJardiance | $264 | $104,20099 claims |
| MerckJanuvia | $35 | $95,000109 claims |
| PfizerEliquis | $320 | $52,60368 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $76 | $39,56575 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $453 | $32,24344 claims |
| AbbVieLinzess, Synthroid | $856 | $31,22269 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $26,40938 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $21 | $21,45618 claims |
| Johnson & JohnsonXarelto | $88 | $14,00219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.